Fig. 3.
FDA stained viable/live H1650 cells and SF767 cells. The number of viable cells decreased with Slit2 addition and with heparin even in presence of TGF-β.
FDA stained viable/live H1650 cells and SF767 cells. The number of viable cells decreased with Slit2 addition and with heparin even in presence of TGF-β.